Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.
作者信息
Yang Eric H, Courtney Cynthia, Garg Vinisha, Fradley Michael G, Schiller Gary J
机构信息
1UCLA Cardio-Oncology Program, Division of Cardiology, Department of Medicine UCLA Cardiovascular Center, 100 Medical Plaza, Suite 630, Los Angeles, CA 90095 USA.
2Division of Hematology and Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA USA.
出版信息
Cardiooncology. 2018 Mar 1;4:2. doi: 10.1186/s40959-018-0028-z. eCollection 2018.
Abstract
Carfilzomib, an epoxyketone proteasome inhibitor, has demonstrated improved progression-free survival in patients when used with standard treatment (lenalidomide and dexamethasone) in patients with relapsed multiple myeloma (MM). However, there are reports of adverse cardiac events with carfilzomib manifested by dyspnea and heart failure. A patient is presented who had recurrent, clinically mild cardiotoxicity, as manifested by recurrent heart failure with preserved ejection fraction, with ongoing maintenance carfilzomib in a patient with resistant MM is presented.
摘要
相似文献
1
Recurrent heart failure with preserved ejection fraction associated with carfilzomib administration for multiple myeloma.
Cardiooncology. 2018 Mar 1;4:2. doi: 10.1186/s40959-018-0028-z. eCollection 2018.
2
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Lancet Oncol. 2018 Jul;19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1. Epub 2018 Jun 1.
3
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
4
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.
5
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.
Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.
6
The First Autopsy Case of Fatal Acute Cardiac Failure after Administration of Carfilzomib in a Patient with Multiple Myeloma.
Case Rep Hematol. 2019 Apr 28;2019:1816287. doi: 10.1155/2019/1816287. eCollection 2019.
7
Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
Intern Med. 2019 Jun 1;58(11):1577-1581. doi: 10.2169/internalmedicine.2194-18. Epub 2019 Feb 1.
8
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Oncologist. 2017 Nov;22(11):1339-1346. doi: 10.1634/theoncologist.2017-0184. Epub 2017 Sep 21.
9
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.
10
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
Lancet. 2020 Jul 18;396(10245):186-197. doi: 10.1016/S0140-6736(20)30734-0.
引用本文的文献
1
Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies: State-of-the-Art Review.
JACC CardioOncol. 2023 Feb 21;5(1):1-21. doi: 10.1016/j.jaccao.2022.12.005. eCollection 2023 Feb.
2
Carfilzomib induced cardiotoxicity in a multiple myeloma patient.
Cardiooncology. 2020 Sep 7;6:17. doi: 10.1186/s40959-020-00074-8. eCollection 2020.
本文引用的文献
1
Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
Cardiovasc Toxicol. 2017 Jul;17(3):237-250. doi: 10.1007/s12012-016-9378-7.
2
Cardiovascular Complications of Novel Multiple Myeloma Treatments.
Circulation. 2016 Mar 1;133(9):908-12. doi: 10.1161/CIRCULATIONAHA.115.018351.
3
Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?
Blood Cancer J. 2016 Jan 15;6(1):e384. doi: 10.1038/bcj.2015.112.
4
Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib.
Blood Cancer J. 2015 Jan 16;5(1):e272. doi: 10.1038/bcj.2014.93.
5
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
N Engl J Med. 2015 Jan 8;372(2):142-52. doi: 10.1056/NEJMoa1411321. Epub 2014 Dec 6.
6
Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring.
BMC Cancer. 2014 Dec 4;14:915. doi: 10.1186/1471-2407-14-915.
7
Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
J Card Fail. 2015 Feb;21(2):138-44. doi: 10.1016/j.cardfail.2014.11.008. Epub 2014 Nov 26.
8
Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies.
Haematologica. 2013 Nov;98(11):1753-61. doi: 10.3324/haematol.2013.089334. Epub 2013 Aug 9.
9
Proteasome inhibitors in multiple myeloma: 10 years later.
Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29.
10
Multiple myeloma.
N Engl J Med. 2011 Mar 17;364(11):1046-60. doi: 10.1056/NEJMra1011442.
Zotero 插件